The comprehensive presentation with Neil Poulter starts with drug choice and sequencing in ISH 2020 and the recommended 2-drug combinations of antihypertensive drugs in the guidelines.
He continues with A&C trials and A+D Trials trying to find an answer for which is the optimal combination.
Afterwards he goes back to the individual drug classes:
- A (ACE-I or ARB)
- Difference between ACE inhibitors and ARBs on mortality reductions in recent meta-analyses
- ARBs missing or fail where ACE-I succeeded
- D (Thiazide-like duretic)
- Indapamide is superior to HCTZ for BP reduction
- Efficacy of diuretics in the hypertension trial (summary)
- C (DHP Calcium Channel Blocker)
The presentation also addresses:
- Guidelines recommendation about triple therapy
- Advantages of Fix Dose combinations (FDC)/Single pill combinations (SPC)
- Efficacy of SPC vs high dose monotherapy
- Adherence FDC and compliance ratio’s
- Initial combination therapy vs initial monotherapy; impact on CV outcomes in Large Case-Control Study
- Summary of benefits of single pill combinations